Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

Immune checkpoint inhibitors in acute myeloid leukemia

(2021) Naval Daver   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

(2021) Kelly S. Chien et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Phagocytic Code Regulating Phagocytosis of Mammalian Cells

(2021) Tom O. J. Cockram et al.   Frontiers in Immunology

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

(2020) Mark P. Chao et al.   Frontiers in Oncology

The CD47-SIRPα Immune Checkpoint

(2020) Meike E.W. Logtenberg et al.   IMMUNITY

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

Role of CD47 in Hematological Malignancies

(2020) Entsar Eladl et al.   Journal of Hematology & Oncology

The promise of macrophage directed checkpoint inhibitors in myeloid malignancies

(2020) David M. Swoboda et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

(2019) Meike E. W. Logtenberg et al.   NATURE MEDICINE

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

(2019) Amer M. Zeidan et al.   BLOOD

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity

(2019) Suresh de Silva et al.   Cancer Immunology Research

Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes

(2018) Benjamin N. Ostendorf et al.   PLoS One

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alternative 3′ UTRs act as scaffolds to regulate membrane protein localization

(2015) Binyamin D. Berkovits et al.   NATURE

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

The key role of calreticulin in immunomodulation induced by chemotherapeutic agents

(2014) Yoshiyuki Yamamura et al.   International Journal of Clinical Oncology

Of macrophages and red blood cells; a complex love story

(2014) Djuna Z. de Back et al.   Frontiers in Physiology

CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome

(2013) Huijuan Jiang et al.   LEUKEMIA RESEARCH

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes

(2013) W. W. Pang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammation-induced proteolytic processing of the SIRPα cytoplasmic ITIM in neutrophils propagates a proinflammatory state

(2013) Ke Zen et al.   Nature Communications

Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis

(2012) T. Kuriyama et al.   BLOOD

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

(2008) T Panaretakis et al.   CELL DEATH AND DIFFERENTIATION

Signal regulatory protein α negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction

(2008) Li-Wei Dong et al.   MOLECULAR IMMUNOLOGY